Philips authorized its largest shareholder to increase its stake to as much as 22%, a move that the Dutch medical technology company frames as a vote of confidence in its long-term strategy. The holding company, Exor, which is controlled by the Agnelli family of Italy, originally bought a 15% stake in 2023 while Philips was still dealing with the fallout from a massive recall of Respironics devices. That initial agreement capped Exor’s ownership at 20%, but the supervisory board can now authorize a higher percentage under the revised long-term arrangement.
Changes to the agreement have altered the terms of the original deal. Exor remains a central part of the conglomerate’s investment portfolio alongside the carmakers Ferrari and Stellantis, and the agriculture and construction player CNH. The company recently sold Lifenet, an Italian manager of hospitals and outpatient clinics, as part of a broader effort to simplify its portfolio. Feike Sijbesma, the chairman of Philips’ supervisory board, described Exor’s continued commitment as reflecting “confidence in Philips and its strategy.” Exor CEO John Elkann echoed that sentiment, stating the revised agreement reflects the investor’s support for the company’s direction.
The structure of this deal allows Exor to deepen its ties with Philips while the parent company implements a new strategy. Sijbesma noted the “constructive engagement” between the two sides, a relationship that includes Benoît Ribadeau-Dumas. Ribadeau-Dumas, an Exor executive who joined Philips’ board in 2024, was recently appointed deputy CEO of Exor, putting a person with direct ties to Philips in a high-level position as the holding company focuses on larger investments.
This alignment of leadership comes as Exor seeks to streamline its operations. By divesting stakes in Lifenet and three other companies, the investor has freed up more than 3.5 billion euros ($4 billion) to pursue new opportunities. Elkann indicated this capital would be used for a significant new investment similar in scale to Philips, effectively pivoting the group’s focus toward fewer, larger assets.
While the board moves to authorize the larger shareholding, the company must still address the financial and operational aftermath of the device recalls. Investors often view a willingness from major shareholders to increase their stake as a sign of stability during turbulent periods. In this case, the increase to 22% signals that Exor believes Philips will weather the current challenges and stabilize its operations. The relationship between the two entities has become increasingly intertwined, with the line between their executive teams blurring as Exor consolidates its influence over its most valuable holding. CMS seeks feedback on the broader regulatory setting surrounding these types of medical devices.
